M&A Deal Summary

Takeda Acquires Inviragen

On May 8, 2013, Takeda acquired healthcare services company Inviragen for 35M USD

Acquisition Highlights
  • This is Takeda’s 1st transaction in the Healthcare Services sector.
  • This is Takeda’s 9th largest (disclosed) transaction.
  • This is Takeda’s 6th transaction in the United States.
  • This is Takeda’s 1st transaction in Colorado.

M&A Deal Summary
Date 2013-05-08
Target Inviragen
Sector Healthcare Services
Buyer(s) Takeda
Deal Type Add-on Acquisition
Deal Value 35M USD

Target

Inviragen

Fort Collins, Colorado, United States
Inviragen is focused on developing vaccines to protect against infectious diseases worldwide.

Search 202,341 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Takeda

Tokyo, Japan
Category Company
Founded 1781
Sector Life Science
Employees47,347
Revenue 4.03T JPY (2023)
DESCRIPTION
Takeda's corporate headquarters in Tokyo, Japan.
Takeda's corporate headquarters in Tokyo, Japan.

Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was originally established in 1781 and is based in Tokyo, Japan.

DEAL STATS #
Overall 8 of 18
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 8 of 15
State (Colorado) 1 of 1
Country (United States) 6 of 12
Year (2013) 1 of 1
Size (of disclosed) 9 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-11-06 Envoy Therapeutics

Jupiter, Florida, United States

Envoy Therapeutics, Inc. is a privately-held drug discovery company focused on finding new drugs with superior efficacy and fewer side effects than existing treatments.

Buy $140M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-16 Takeda Pharmaceutical Company - Core Respiratory Business

Japan

Takeda Pharmaceutical Company Limited's core respiratory business includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).

Sell $575M
Mergr

Product

Company

Legal